Aviceda Receives the US FDA’s IND Clearance of AVD-104 for the Treatment of Geographic Atrophy from Macular Degeneration
Shots:
- The US FDA has cleared the IND to initiate the P-II clinical trials (SIGLEC) of AVD-104, an intravitreal nanoparticle molecule with a unique dual MoA for treating GA secondary to AMD. The trial is expected to be initiated in Q2’23
- AVD-104 showed robust in-vitro/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for q4-6mos. dosing. Numerous animal models, incl. non-human primates have shown outstanding safety with no evidence of intra-ocular inflammation
- In the ocular CNV model, AVD-104 showed anti-neovascular activity comparable to Eylea (aflibercept). The company is working on many different therapeutic areas, inc. ophthalmology in its extensive product pipeline
Ref: Businesswire | Image: Aviceda
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
